Andere Sprachen OncoZenge AB

Aktien

A2QNQR

SE0015504097

ONCOZ

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:35 26.04.2024			% 5 Tage	% 1. Jan.
3.895 ^SEK	+0.13%		-5.23%	+26.05%

08.04.	Oncozenge AB (Publ) ernennt Paolo Bossi zum Mitglied des Beirats	CI
04.04.	OncoZenge gibt die Veröffentlichung positiver Stabilitätsdaten für BupiZenge bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

OncoZenge Appoints Anna Asplind as Phase 3 Program Manager	26.04.
OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs	25.04.
OncoZenge Appoints Åsa Nilsson as Clinical Research Manager	09.04.
OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board	08.04.
Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board	08.04.
OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™	04.04.
OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge	04.04.
Oncozenge Explores Strategic Options for Bupizeng in China	11.03.
OncoZenge Explores Strategic Options for BupiZenge™ in China	11.03.
OncoZenge AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15.02.
OncoZenge Seeks to Expand Patent Protection for Oral Lozenge Product BupiZenge	07.02.
OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™	07.02.
OncoZenge AB Files Patent Application for Strengthened IP Protection for BupiZenge	07.02.
OncoZenge Seeks Priority Medicines Status for Oral Pain Treatment in Europe	02.01.
OncoZenge submits application for PRIME status in the EU	02.01.
OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel	13.12.
Oncozenge Announces Formation of Advisory Board with Stephen Sonis and Pooja Nandwani Patel	13.12.
Ensysce Biosciences Discusses TAAP and MPAR Applications and OncoZenge Partnership with the Stock Day Podcast	12.12.
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States	28.11.
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States	28.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen OncoZenge AB

Aktien

A2QNQR

SE0015504097

ONCOZ

Andere Sprachen

Filter